Evidence map›Paper›PMID 29263902›Full record

ArticleSignal transduction and targeted therapy

USP21 deubiquitylates Nanog to regulate protein stability and stem cell pluripotency.

Xingyu Liu, Yuying Yao, Huiguo Ding, Chuanchun Han, Yuhan Chen, Yuan Zhang, Chanjuan Wang, Xin Zhang, Yiling Zhang, Yun Zhai and 4 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Signal transduction and targeted therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 80 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Xingyu LiuDepartment of Hepatology and Gastroenterology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Yuying YaoInstitute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Huiguo DingDepartment of Hepatology and Gastroenterology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Chuanchun HanInstitute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Yuhan ChenState Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Collaborative Innovation Center for Cancer Medicine, Beijing, China.
Yuan ZhangState Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Collaborative Innovation Center for Cancer Medicine, Beijing, China.
Chanjuan WangState Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Collaborative Innovation Center for Cancer Medicine, Beijing, China.
Xin ZhangCollege of Life Sciences, Xiamen University, Xiamen, China.
Yiling ZhangDepartment of Orthopedics, the General Hospital of Chinese People's Liberation Army, Beijing, China.
Yun ZhaiDepartment of Hepatology and Gastroenterology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Ping WangShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Wenyi WeiDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Jing ZhangDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Lingqiang ZhangState Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Collaborative Innovation Center for Cancer Medicine, Beijing, China.
Capital Medical University · CNDalian Medical University · CNBeijing Proteome Research Center · CNPeople's Liberation Army No. 150 Hospital · CNBeth Israel Deaconess Medical Center · USEast China Normal University · CNIndiana University School of MedicineXiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The homeobox transcription factor Nanog has a vital role in maintaining pluripotency and self-renewal of embryonic stem cells (ESCs). Stabilization of Nanog proteins is essential for ESCs. The ubiquitin-proteasome pathway mediated by E3 ubiquitin ligases and deubiquitylases is one of the key ways to regulate protein levels and functions. Although ubiquitylation of Nanog catalyzed by the ligase FBXW8 has been demonstrated, the deubiquitylase that maintains the protein levels of Nanog in ESCs yet to be defined. In this study, we identify the ubiquitin-specific peptidase 21 (USP21) as a deubiquitylase for Nanog, but not for Oct4 or Sox2. USP21 interacts with Nanog protein in ESCs

Identifiers

PMID29263902
PMCPMC5661642
OpenAlexW2548295067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.